Health
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide – PRNewswire
/PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg……
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University of Melbourne, Parkville, Victoria. Vosoritide…
-
Noosa News15 hours agoSearch for man who ‘faked death’ slowed by unusual French law
-
General13 hours agoMatildas vs Panama international friendly — live blog and scores from Bunbury
-
Noosa News21 hours agoQueensland Rail retires iconic electric train fleet after more than four decades
-
Business18 hours ago2 ASX 200 large-cap shares that this fundie is cashing in after phenomenal growth